Cargando…

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

AIM: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Because of the large interpatient pharmacokinetic variability and established exposure‐response and exposure‐toxicity relationships in clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westerdijk, Kim, Krens, Stefanie D., van der Graaf, Winette T.A., Mulder, Sasja F., van Herpen, Carla M.L., Smilde, Tineke, van Erp, Nielka P., Desar, Ingrid M.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Precision Medicine‐based Drug Treatment Individualization in Oncology–Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328649/ https://www.ncbi.nlm.nih.gov/pubmed/32358810 http://dx.doi.org/10.1111/bcp.14332

Ejemplares similares

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study
por: Mulder, Sasja F, et al.
Publicado: (2014)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction
por: Veenis, Jesse F, et al.
Publicado: (2019)

Coalitional Game Theory Facilitates Identification of Non-Coding Variants Associated With Autism
por: Sun, Min Woo, et al.
Publicado: (2019)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry study
por: Wallert, John, et al.
Publicado: (2017)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Incidence and factors associated with prescribing renin‐angiotensin‐system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study
por: Nishiwaki, Hiroki, et al.
Publicado: (2021)

Post-treatment Stage of Change Predicts 12-month Outcome of Treatment for Alcohol Problems
por: Heather, Nick, et al.
Publicado: (2013)

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
por: Hoes, Louisa R., et al.
Publicado: (2022)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
por: Giraud, Eline L., et al.
Publicado: (2023)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients
por: Soomers, Vicky, et al.
Publicado: (2020)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study
por: Desar, I.M.E., et al.
Publicado: (2011)

Cytokine Mixtures Mimicking the Local Milieu in Patients with Inflammatory Bowel Disease Impact Phenotype and Function of Mesenchymal Stromal Cells
por: Barnhoorn, Marieke C, et al.
Publicado: (2022)

FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases
por: De Vos, Filip YFL, et al.
Publicado: (2013)

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location
por: den Hollander, Dide, et al.
Publicado: (2020)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Clinical importance of urinary sodium excretion in acute heart failure
por: Damman, Kevin, et al.
Publicado: (2020)

48352 Mechanisms Underlying Lipidomic Changes in Major Depressive Disorder
por: Costa, Ana Paula, et al.
Publicado: (2021)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2023)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes
por: Soomers, Vicky, et al.
Publicado: (2020)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
por: Gerritse, Sophie L., et al.
Publicado: (2022)

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies
por: van den Brink, Wim, et al.
Publicado: (2013)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Remote Patient Monitoring for Patients with Heart Failure: Sex- and Race-based Disparities and Opportunities
por: Mastoris, Ioannis, et al.
Publicado: (2023)

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)
por: Gvozdenović, Emilia, et al.
Publicado: (2016)

Systemic Treatment for Adults with Synovial Sarcoma
por: Desar, Ingrid M. E., et al.
Publicado: (2018)

Mesenchymal Stromal Cells Modulate Corneal Alloimmunity via Secretion of Hepatocyte Growth Factor
por: Mittal, Sharad K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oa2l9a4f5091ohib21ttofk93q